Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.

Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.

In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.

Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.

Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.

Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.

In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.

Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.